Hangzhou Diagens Biotechnology (HKG:2526) entered a three-year cooperation framework agreement with Zhejiang Anzhen'er Medical Artificial Intelligence Technology to develop medical imaging AI, primary-care imaging cloud services and medical data products.
The companies will combine Diagens' iMedImage medical imaging capabilities with Anzhen'er's medical institution resources to explore an AI-assisted imaging diagnosis cloud platform in Zhejiang, according to a Friday Hong Kong bourse filing.
The cooperation will also cover the development of medical datasets, AI training data and research and data analysis products.